气喘市场:KOL的洞察

本报告提供全球气喘市场相关调查，提供市场概要，以及已上市治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

治疗流程

调查目的

生物学的疗法

• 已通过核准治疗方法
  • 抗 IL5 疗法：Nucala（美泊利单抗；GSK）和 Fasenra（贝那利珠单抗；阿斯特捷利康）
  • 抗 IL4/IL13 疗法：Dupixent（Dupilumab、Regeneron/Sanofi）
  • 抗 TSLP 疗法：Tezspire（tezepelumab、Amgen/AstraZeneca）
• 开发平台(管线)的治疗方法
  • 抗 IL5 疗法：depemokimab（GSK3511294；GSK）

ICS/LABA/LAMA三倍联合治疗

• Trelegy Ellipta（糠酸氟替卡松/umeclidinium/vilanterol；GSK）、Enerzair Breezhaler（格隆铵/?达特罗/莫米松；诺华）、Trimbow（倍氯米松/福莫特罗/格隆铵； Chiesi）(8)
• 开发平台(管线)的治疗方法
  • Breztri/Trixeo Aerosphere(Budesonide/Budesonide/gurikopironiumu;AstraZeneca)(10)

双重固定联合治疗

• 已通过核准治疗方法
  • Airsupra（沙丁胺醇[沙丁胺醇]/布地奈德；阿斯特捷利康/Avillion）
• 管道处理
  • TEV-56248（硫酸沙丁胺醇/丙酸氟替卡松；Teva）

其他的作用机制

• 开发平台(管线)的治疗方法
  • 右旋普拉克索 (Areteia Therapeutics)

未来的治疗范例

附录

KOL报告书

Why do KOLs say GSK's next-generation anti-IL5 mAb depemokimab has the potential to impact the uptake of the established anti-IL5 therapies? What factors are hindering the initial uptake of AstraZeneca/Amgen's novel anti-TSLP mAb, Tezspire, and what could shape its future? Why are KOLs positive about the value of Sanofi/Regeneron's Dupixent in paediatric therapy? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (10)

Treatment algorithm

Research objectives (9)

Biologic therapies (43)

• Approved therapies (34)
  • Anti-IL5 therapies: Nucala (mepolizumab; GSK) and Fasenra (benralizumab; AstraZeneca) (8)
  • Anti-IL4/IL13 therapies: Dupixent (dupilumab; Regeneron/Sanofi) (12)
  • Anti-TSLP therapies: Tezspire (tezepelumab; Amgen/AstraZeneca) (14)
• Pipeline therapies (9)
  • Anti-IL5 therapies: depemokimab (GSK3511294; GSK) (9)

ICS/LABA/LAMA triple combination therapies (18)

• Approved therapies (8)
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; GSK), Enerzair Breezhaler (glycopyrronium/indacaterol/mometasone; Novartis) and Trimbow (beclometasone/formoterol/glycopyrronium; Chiesi) (8)
• Pipeline therapies (10)
  • Breztri/Trixeo Aerosphere (budesonide/formoterol/glycopyrronium; AstraZeneca) (10)

Dual fixed-combination therapies (21)

• Approved therapies (11)
  • Airsupra (salbutamol [albuterol]/budesonide; AstraZeneca/Avillion) (11)
• Pipeline therapies (10)
  • TEV-56248 (albuterol sulfate/fluticasone propionate; Teva) (10)

Other mechanisms of action (11)

• Pipeline therapies (11)
  • Dexpramipexole (Areteia Therapeutics) (11)

Future treatment paradigm (9)

• Key insights summary (9)

Appendix (4)

• KOL details (4)
  • KOLs from the USA (1)
  • KOLs from Europe (2)